subscribeSubscribe
InnoCare`s Tafasitamab BLA Accepted For DLBCL Treatment In China

InnoCare`s Tafasitamab BLA Accepted For DLBCL Treatment In China
BUSINESSWIRE
20 Jun 2024
Share Share
Enterome updates clinical data from ongoing EONHL1-20/SIDNEY trial EO2463

Enterome updates clinical data from ongoing EONHL1-20/SIDNEY trial EO2463
PHARMABIZ
27 May 2024
Share Share
Dr Reddy`s healthy Q4 results fail to impress brokerages

Dr Reddy`s healthy Q4 results fail to impress brokerages
MONEYCONTROL
08 May 2024
Share Share
Bristol Myers to cut 6% of workforce, trim drug pipeline

Bristol Myers to cut 6% of workforce, trim drug pipeline
Ned Pagliarulo BIOPHARMADIVE
25 Apr 2024
Share Share
EC Approves Carvykti for RRMM| Int`l Myeloma Foundation

EC Approves Carvykti for RRMM| Int`l Myeloma Foundation
PRESS RELEASE
22 Apr 2024
Share Share
IASO NMPA`s IND Approval for Equecabtagene Autoleucel for Treatment of Myeloma

IASO NMPA`s IND Approval for Equecabtagene Autoleucel for Treatment of Myeloma
PR NEWSWIRE
29 Mar 2024
Share Share
Pfizer`s blood cancer therapy Adcetris succeeds in late-stage trial

Pfizer`s blood cancer therapy Adcetris succeeds in late-stage trial
PRESS RELEASE
13 Mar 2024
Share Share
Qilu`s Generic Lenalidomide Receives Approval in the U.S.

Qilu`s Generic Lenalidomide Receives Approval in the U.S.
FDA
22 Feb 2024
Share Share
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program

InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
BUSINESSWIRE
21 Jan 2024
Share Share
Starton Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Trial

Starton Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Trial
BUSINESSWIRE
04 Oct 2023
Share Share